Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Long-Term Investments (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Long-Term Investments readings, the most recent being $1.1 billion for Q4 2025.

  • On a quarterly basis, Long-Term Investments rose 43.75% to $1.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 billion, a 43.75% increase, with the full-year FY2025 number at $1.1 billion, up 43.75% from a year prior.
  • Long-Term Investments hit $1.1 billion in Q4 2025 for Neurocrine Biosciences, up from $998.5 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $1.1 billion in Q4 2025 to a low of $244.6 million in Q1 2023.
  • Median Long-Term Investments over the past 5 years was $550.8 million (2021), compared with a mean of $573.6 million.
  • Biggest five-year swings in Long-Term Investments: crashed 54.79% in 2023 and later skyrocketed 186.35% in 2024.
  • Neurocrine Biosciences' Long-Term Investments stood at $560.7 million in 2021, then crashed by 46.6% to $299.4 million in 2022, then surged by 129.63% to $687.5 million in 2023, then rose by 7.56% to $739.5 million in 2024, then surged by 43.75% to $1.1 billion in 2025.
  • The last three reported values for Long-Term Investments were $1.1 billion (Q4 2025), $998.5 million (Q3 2025), and $873.8 million (Q2 2025) per Business Quant data.